These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 16261634)

  • 21. The antithrombotic and anti-inflammatory effects of BCX-3607, a small molecule tissue factor/factor VIIa inhibitor.
    Arnold CS; Parker C; Upshaw R; Prydz H; Chand P; Kotian P; Bantia S; Babu YS
    Thromb Res; 2006; 117(3):343-9. PubMed ID: 16378835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simulation of a mathematical model of the role of the TFPI in the extrinsic pathway of coagulation.
    Xu C; Hu Xu X; Zeng Y; Wen Chen Y
    Comput Biol Med; 2005 Jun; 35(5):435-45. PubMed ID: 15767116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
    Gosk-Bierska I; Wysokin Ski W; Karnicki K; Adamiec R
    Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis.
    Kaiser B; Fareed J
    Thromb Haemost; 1996 Oct; 76(4):615-20. PubMed ID: 8903005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity.
    Li A; Wun TC
    Thromb Haemost; 1998 Sep; 80(3):423-7. PubMed ID: 9759622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relevance of tissue factor in cardiovascular disease.
    Jude B; Zawadzki C; Susen S; Corseaux D
    Arch Mal Coeur Vaiss; 2005 Jun; 98(6):667-71. PubMed ID: 16007822
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue factor pathway inhibitor: new insights into an old inhibitor.
    Adams M
    Semin Thromb Hemost; 2012 Mar; 38(2):129-34. PubMed ID: 22422327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
    Lizakowski S; Zdrojewski Z; Jagodzinski P; Rutkowski B
    Scand J Urol Nephrol; 2007; 41(3):237-42. PubMed ID: 17469034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
    Cunningham AC; Hasty KA; Enghild JJ; Mast AE
    Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacological profiling of recombinant tissue factor pathway inhibitor.
    Jeske W; Hoppensteadt D; Callas D; Koza MJ; Fareed J
    Semin Thromb Hemost; 1996; 22(2):213-9. PubMed ID: 8807720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue factor pathway.
    McVey JH
    Baillieres Clin Haematol; 1994 Sep; 7(3):469-84. PubMed ID: 7841596
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant tissue factor pathway inhibitor enhances the binding of factor Xa to human monocytes.
    Li A; Chang AC; Peer GT; Wun TC; Taylor FB
    Thromb Haemost; 2001 May; 85(5):830-6. PubMed ID: 11372676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue factor pathway inhibitor (TFPI).
    Rucińska M; Gacko M; Skrzydlewski Z
    Rocz Akad Med Bialymst; 1997; 42 Suppl 1():118-22. PubMed ID: 9337530
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein S is a cofactor for tissue factor pathway inhibitor.
    Rosing J; Maurissen LF; Tchaikovski SN; Tans G; Hackeng TM
    Thromb Res; 2008; 122 Suppl 1():S60-3. PubMed ID: 18691502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue factor pathway inhibitor.
    Camici M; Sagripanti A
    Minerva Med; 1999; 90(1-2):25-32. PubMed ID: 10388460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of recombinant human tissue factor pathway inhibitor on thrombus formation and its in vivo distribution in a rat DIC model.
    Elsayed YA; Nakagawa K; Kamikubo YI; Enjyoji KI; Kato H; Sueishi K
    Am J Clin Pathol; 1996 Nov; 106(5):574-83. PubMed ID: 8929465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue factor upregulation drives a thrombosis-inflammation circuit in relation to cardiovascular complications.
    Chu AJ
    Cell Biochem Funct; 2006; 24(2):173-92. PubMed ID: 15617024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders.
    Kaiser B; Hoppensteadt DA; Fareed J
    Expert Opin Investig Drugs; 2001 Nov; 10(11):1925-35. PubMed ID: 11772296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor Xa cleavage of tissue factor pathway inhibitor is associated with loss of anticoagulant activity.
    Salemink I; Franssen J; Willems GM; Hemker HC; Li A; Wun TC; Lindhout T
    Thromb Haemost; 1998 Aug; 80(2):273-80. PubMed ID: 9716152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons.
    Lupu C; Kruithof EK; Kakkar VV; Lupu F
    Thromb Haemost; 1999 Dec; 82(6):1652-8. PubMed ID: 10613651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.